{"filing":{"accession_number":"0001493152-26-034334","cik":"0001419554","ticker":"BBLGW","company_name":"Bone Biologics Corp","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1419554/000149315226034334/form8-k.htm"},"events":[{"id":19857,"run_id":17871,"accession_number":"0001493152-26-034334","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"This is a mid-year shareholder update disclosing progress on multiple operational and clinical milestones: advancement of the NB1 first-in-human clinical study, extension of rhNELL-1 shelf life to 29 months, intellectual property initiatives, and a recently completed $3.0 million private placement financing. While the financing component could suggest dilutive_issuance, the press release centers on operational and clinical progress rather than the equity issuance itself, making operational_other the most appropriate classification. The disclosure is material as it updates investors on clinical development, manufacturing readiness, and capital runway through Q2 2027.","company_name":"Bone Biologics Corp","ticker":"BBLGW","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19064,"accession_number":"0001493152-26-034334","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"This is a mid-year shareholder update disclosing progress on multiple operational and clinical milestones: advancement of the NB1 first-in-human clinical study, extension of rhNELL-1 shelf life to 29 months, intellectual property initiatives, and a recently completed $3.0 million private placement financing. While the financing component could suggest dilutive_issuance, the press release centers on operational and clinical progress rather than the equity issuance itself, making operational_other the most appropriate classification. The disclosure is material as it updates investors on clinical development, manufacturing readiness, and capital runway through Q2 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T12:06:37.555183+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19064,"accession_number":"0001493152-26-034334","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"This is a mid-year shareholder update disclosing progress on multiple operational and clinical milestones: advancement of the NB1 first-in-human clinical study, extension of rhNELL-1 shelf life to 29 months, intellectual property initiatives, and a recently completed $3.0 million private placement financing. While the financing component could suggest dilutive_issuance, the press release centers on operational and clinical progress rather than the equity issuance itself, making operational_other the most appropriate classification. The disclosure is material as it updates investors on clinical development, manufacturing readiness, and capital runway through Q2 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T12:06:37.555183+00:00","company_name":"Bone Biologics Corp","ticker":"BBLGW","filing_date":"2026-07-23"}]}